Method and pharmaceutical formulation for treating benign prostatic hyperplasia
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 11, 2000
Issued Date -
N/A
app pub date -
Nov 24, 1997
filing date -
Apr 7, 1992
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Benign prostatic hyperplasia (BPH) in male humans is treated by administering to a male patient in which such condition has been diagnosed, an effective BPH treating amount within the range of from 1 ng to 80 mg of melatonin, which may be in the form of a pharmaceutical formulation for use in treating BPH, which comprises, in combination a carrier, diluent or adjuvant, (1) an effective BPH treating amount of melatonin; and optionally (2) antiandrogens, antiestrogens, growth hormones and/or inhibitors of prostatal testosterone reductase; and/or (3) oxazepam or other melatonin receptor profile modifier.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully